---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-134447"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:57:11.953723+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics initiates Phase 3 EMPEROR study of zorevunersen; first US sites in May 2025

## Summary
- Initiated Phase 3 EMPEROR study of zorevunersen; first U.S. sites activated in May 2025.
- Updated corporate presentation posted to website on June 4, 2025, for Jefferies Global Healthcare Conference.
- No other material financial or operational updates disclosed beyond the study initiation.

## SEC filing metadata
- accession: 0001193125-25-134447
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525134447/0001193125-25-134447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525134447/d36270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-134447
- JSON: https://secwatch.observer/filing/0001193125-25-134447.json
- Plain text: https://secwatch.observer/filing/0001193125-25-134447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.